SpinaFX Medical Inc., a Canada-based minimally invasive image-guided therapy start-up, announced on Friday that it has named John Soloninka as its new chief operating officer.
Soloninka has served as a healthtech entrepreneur and ex IBM and Price Waterhouse healthcare system strategist. He has held the position of a CEO and co-founded a USD28m public/private venture debt fund, overseeing a syndicated CAD86M investment in 36 early-stage Healthtech companies including Synaptive Medical, CONAVI, SPARTAN, and Profound Medical. He also co-founded an AI-based oncology management company, ultimately acquired by Varian Medical Systems, and co-founded and headed product development and operations for a cloud-based medical imaging company sold to Merge Technologies of Milwaukee, which was ultimately purchased by IBM. He has served in the research and commercialisation advisory posts with the Rotman Research Institute and the Ontario Brain Institute, and as an expert witness to Canada's Standing Parliamentary Committee on Healthcare.
Soloninka holds a BSc in Engineering Physics from Queen's University and an MBA with Distinction from the Imperial College Business School, London UK.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients